Glate 0.2mg Injection 1ml

Glate 0.2mg Injection 1ml contains glycopyrrolate, a quaternary ammonium anticholinergic agent that blocks muscarinic acetylcholine receptors in smooth muscle, glandular tissue, and the cardiac conduction system.

Unlike tertiary anticholinergics such as atropine, glycopyrrolate does not cross the blood-brain barrier, which means it exerts its effects peripherally without causing central nervous system side effects. This makes it particularly suitable for use in patients where central anticholinergic effects are undesirable.

Its principal clinical applications include reducing excessive salivation and respiratory secretions, managing peptic ulcer disease by reducing gastric acid secretion, controlling hyperhidrosis, and as a preoperative agent to reduce secretions during anaesthesia.

The uses of Glate 0.2mg Injection 1ml are as follows:

Excessive Salivation (Sialorrhoea)

Glate 0.2mg Injection 1ml is used to reduce abnormal drooling in conditions such as cerebral palsy and Parkinson's disease.

Peptic Ulcer Disease

It reduces gastric acid and secretions, helping manage symptoms associated with peptic ulcers.

Hyperhidrosis

It is used to reduce excessive sweating that does not respond to topical treatments.

Preoperative Use

It is administered before surgery to reduce oral and respiratory secretions during anaesthesia.

Overactive Bladder

It helps reduce urinary urgency and frequency by relaxing bladder smooth muscle.

Chronic Obstructive Pulmonary Disease (COPD)

Inhaled glycopyrrolate is used as a bronchodilator to improve airflow in COPD.

Here are the benefits of Glate 0.2mg Injection 1ml:

• Peripheral Selectivity: Unlike many anticholinergics, glycopyrrolate does not cross the blood-brain barrier, reducing the risk of central side effects such as confusion.

• Reduces Excessive Secretions: Effectively controls salivation and respiratory secretions in both medical and surgical settings.

• Manages Gastric Acid: Reduces gastric secretions, providing symptomatic relief in peptic ulcer disease.

• Controls Hyperhidrosis: Provides meaningful reduction in excessive sweating where other treatments have failed.

• Bronchodilation in COPD: Inhaled formulations improve airflow and reduce breathlessness in COPD patients.

Like all medicines, Glate 0.2mg Injection 1ml may cause side effects in some individuals.

Common Side Effects

• Dry Mouth: Reduced salivary secretion is the most commonly reported side effect.

• Constipation: Reduced bowel motility may cause infrequent or difficult bowel movements.

• Urinary Retention: Difficulty passing urine may occur, particularly in older males.

• Blurred Vision: Reduced accommodation due to pupillary dilation may affect near vision.

Uncommon Side Effects

• Palpitations: Mild increase in heart rate may be noticed.

• Skin Flushing: Reduced sweating may cause skin warmth and flushing.

• Headache: Mild headache may develop during early use.

Serious Side Effects (Require Immediate Medical Attention)

• Acute Urinary Retention: Complete inability to pass urine requires urgent medical attention.

• Severe Tachycardia: Rapid or irregular heartbeat should be evaluated promptly.

• Acute Angle-Closure Glaucoma: Sudden eye pain or vision changes require immediate review.

Always consult your doctor if side effects persist or worsen.

To ensure safe use:

• Use exactly as prescribed by your doctor.

• Oral formulations are usually taken with or without food as directed.

• Inhaled formulations should be used with the correct device and technique.

• Do not exceed the prescribed dose or frequency.

• Inform your doctor if urinary symptoms or vision changes develop.

Glycopyrrolate competitively blocks muscarinic acetylcholine receptors at parasympathetic nerve endings in glandular tissue, smooth muscle, and the heart. This inhibits the effects of acetylcholine, reducing glandular secretions including saliva, sweat, and gastric acid, relaxing smooth muscle in the bladder, gastrointestinal tract, and bronchi, and mildly increasing heart rate by reducing vagal tone.

Because glycopyrrolate is a quaternary ammonium compound, it carries a permanent positive charge that prevents it from crossing the blood-brain barrier, confining its action to the peripheral nervous system and avoiding central anticholinergic effects.

A few practical measures can help ensure safe use of Glate 0.2mg Injection 1ml:

• Stay hydrated: Dry mouth and reduced sweating may increase dehydration risk, particularly in hot weather.

• Inform your doctor of eye conditions: Glycopyrrolate can precipitate acute angle-closure glaucoma in predisposed individuals.

• Use the correct inhaler technique: For COPD formulations, proper device use is essential for effective bronchodilation.

• Monitor urinary symptoms: Report any difficulty passing urine promptly, particularly in older male patients.

• Avoid overheating: Reduced sweating impairs the body's ability to regulate temperature in hot environments.

• Store at room temperature: Keep away from heat, moisture, and direct sunlight.

• Keep in original packaging: Protects the medicine from humidity and light exposure.

• Keep out of reach of children: Store safely to prevent accidental ingestion.

• Check expiry before use: Do not use after the expiry date.

• Avoid excessive alcohol: May worsen dry mouth and dizziness associated with anticholinergic effects.

• Adequate fluid intake: Helps manage dry mouth and supports normal bowel and urinary function.

• No significant food interactions: Oral formulations may be taken with or without food as directed.

• Other Anticholinergics: Combined use increases the risk of anticholinergic side effects including urinary retention and constipation.

• Antihistamines: Many antihistamines have anticholinergic properties and may compound side effects.

• Tricyclic Antidepressants: Additive anticholinergic effects may increase dry mouth, constipation, and urinary retention.

• Opioid Analgesics: Combined use may worsen constipation and urinary retention.

• Glaucoma: Glycopyrrolate may precipitate acute angle-closure glaucoma in susceptible individuals.
• Benign Prostatic Hyperplasia: Urinary retention risk is significantly increased in men with prostate enlargement.
• Myasthenia Gravis: Anticholinergic medicines may worsen neuromuscular transmission impairment.
• Ulcerative Colitis: Reduced bowel motility may worsen colitis or precipitate toxic megacolon.
• Cardiac Arrhythmias: Increased heart rate may worsen tachyarrhythmias in susceptible patients.

Dose and frequency depend on the formulation and clinical indication. Always follow your doctor's specific instructions.

If a dose is missed, take it as soon as remembered, but do not double the dose to make up for a missed one.